Company: SNWV
Filing Date: 2025-07-10
Form Type: DEF 14A
Source: 0001140361-25-025486
Chunk: 25

Company: SANUWAVE Health, Inc.
Filing Date: 2025-07-10
Form: DEF 14A
Chunk 25
---
 reviews our long-term incentive compensation program to ensure that we balance our employee compensation objectives with our stockholders’ interest in limiting dilution from equity awards. The following table sets forth information regarding stock and option awards that were outstanding and shares available for future grants under the 2024 Plan as of the Record Date. As of the Record Date, we had 1,283,645 shares of common stock underlying equity awards outstanding under the 2024 Plan and 22,031 shares of common stock underlying equity awards outstanding under the Amended and Restated 2006 Stock Incentive Plan of SANUWAVE Health, Inc. (the “2006 Plan”). No further awards may be issued under the 2006 Plan. The market value of one share of our common stock on the Record Date, as determined based on the closing price per share of our common stock as reported on Nasdaq, was $34.89.

|           |     |                 Number of 
          securities to be 
               issued upon 
 exercise or settlement of 
        outstanding awards |     |      Weighted- 
        average 
 exercise price 
 of outstanding 
        options |     |  Weighted- 
    average 
    term to 
 expiration |     |       Number of 
      securities 
       remaining 
   available for 
 future issuance |
| 2006 Plan |     |                    22,031 |     |         $56.22 |     |        2.2 |     |               — |
| 2024 Plan |     |                 1,283,645 |     |         $18.45 |     |        9.2 |     |          70,722 |
| Total     |     |                 1,305,676 |     |         $19.09 |     |        9.0 |     |          70,722 |

Overhang . As of the Record Date, the outstanding equity awards under the 2024 Plan and 2006 Plan, together with the number of shares available for future grants of equity awards under the 2024 Plan (commonly referred to as the “overhang”), represent approximately 13.5% of the fully diluted number of shares of our common stock. The dilutive impact of the additional 500,000 shares that would be available for issuance under the 2024 Plan would increase the overhang by approximately four percentage points to approximately 17.5% based on our fully diluted number of shares of our common stock as of the Record